Biocon to merge biologics unit in $5.5 billion deal
Biocon has announced a bold step in the biopharmaceutical landscape by merging its biosimilars division, Biocon Biologics, into the parent organization for $5.5 billion. This ambitious strategy is designed to streamline operations and amplify its influence across global markets, especially in diabetes care, cancer treatment, and immune therapies.
Biocon has announced a bold step in the biopharmaceutical landscape by merging its biosimilars division, Biocon Biologics, into the parent organization for $5.5 billion. This ambitious strategy is designed to streamline operations and amplify its influence across global markets, especially in diabetes care, cancer treatment, and immune therapies.
